Cytokinetics CYTK Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's total equity?
- Cytokinetics (CYTK) reported total equity of -$826.57M in Q1 2026.
- How has Cytokinetics's total equity changed year-over-year?
- Cytokinetics's total equity decreased by 210.3% year-over-year, from -$266.41M to -$826.57M.
- What is the long-term trend for Cytokinetics's total equity?
- Over 5 years (2020 to 2025), Cytokinetics's total equity has grown at a 42.2% compound annual growth rate (CAGR), from $113.38M to -$659.63M.
- What does total equity mean?
- The total net value of the company belonging to its shareholders.
- How do you interpret total equity?
- An increase signals capital accumulation or profitable operations, while a decrease may signal losses or share buybacks.
- How does total equity compare across companies?
- A key indicator of the company's net worth and financial health relative to its peers.